ArriVent BioPharma (AVBP) EPS (Weighted Average and Diluted) (2023 - 2026)
ArriVent BioPharma's (AVBP) quarterly EPS (Weighted Average and Diluted) came in at -$0.96 in Q1 2026, up 49.47% year-on-year from -$0.64 in Q1 2025, and down 23.08% quarter-over-quarter from -$0.78 in Q4 2025.
ArriVent BioPharma (AVBP) EPS (Weighted Average and Diluted) (2023 - 2026) Analysis & Trends
ArriVent BioPharma has disclosed EPS (Weighted Average and Diluted) across 4 years of filings, most recently posting -$0.96 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.96, up 49.47% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.47 (up 7.96% YoY), and the FY2025 annual result was -$4.32, down 68.75% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.96 for Q1 2026 at ArriVent BioPharma, down from -$0.78 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.61 in Q3 2024 to a low of -$10.79 in Q2 2023.
- The 4-year median for EPS (Weighted Average and Diluted) is -$0.9 (2025), against an average of -$3.18.
- Across the five-year window, EPS (Weighted Average and Diluted) surged 93.98% in 2024 and plunged 171.43% in 2025, its largest moves.
- ArriVent BioPharma's EPS (Weighted Average and Diluted) stood at -$7.69 in 2023, then jumped by 92.07% to -$0.61 in 2024, then slipped by 27.87% to -$0.78 in 2025, then fell by 23.08% to -$0.96 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.96 (Q1 2026), -$0.78 (Q4 2025), and -$0.83 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | ArriVent BioPharma | 1.37 Bn | 1.37 Bn | - | -0.96 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.96 |
| Dec 31, 2025 | -0.78 |
| Sep 30, 2025 | -0.83 |
| Jun 30, 2025 | -0.90 |
| Mar 31, 2025 | -1.90 |
| Dec 31, 2024 | -0.61 |
| Sep 30, 2024 | -0.61 |
| Jun 30, 2024 | -0.65 |
| Mar 31, 2024 | -0.70 |
| Dec 31, 2023 | -7.69 |
| Sep 30, 2023 | -5.52 |
| Jun 30, 2023 | -10.79 |
| Mar 31, 2023 | -9.45 |